|
|
|
|
home > abstracts >
Fajardo M, Di Cesare PE
|
|
 |
Fajardo M, Di Cesare PE.
Drugs & Aging 2005;22:141-161.
Osteoarthritis (OA), the most common form of arthritis, is a debilitating progressive disease principally affecting the elderly. OA therapy has evolved in the past few decades from symptomatic treatment to possible disease-modifying solutions. This article includes the pathophysiology of OA including an examination of the mechanisms underlying osteoarthritis and discussions of the roles of cartilage, synovial fluid and subchondral bone is first reviewed. The remainder discusses therapeutic approaches in current use and those in development, with special attention given to pharmacological treatments. Other established and experimental therapies that seek to modify and/or even reverse the course of osteoarthritis are also reviewed including colchicine, bisphosphonates and hormones; dietary therapeutics; and experimental treatments as matrix metalloproteinase inhibitors, cytokines, nitric oxide, growth factors and gene therapy.
OA continues to be a difficult disorder to treat, as no cure exists and current treatments focus primarily on relieving pain and maintaining joint function. The search nevertheless continues for management regimens that can slow, alter or reverse the degenerative processes of OA.
|
© Johnson & Johnson Inc. 2001-2010
This site is published by McNeil Consumer Healthcare, division of Johnson & Johnson Inc.
which is solely responsible for its content.
It is intended for visitors from Canada only.
See our Legal Notice and Privacy Policy
Last updated: September 03rd, 2007
|
|
|
| |
|
 |
 |
|
| |
The lecture on epidemiology also provides insights into the impact of musculoskeletal diseases.
|
 |
| |
|
|
|
|
|
|
|
|
 |
|
|
| |
arthritisU.com
pays special attention to various aspects of osteoarthritis
(OA) from epidemiology to clinical practice. |
 |
| |
more |
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
|
|
|
